Trial Profile

A clinical trial of XVR 013 for COVID-2019 infections

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XVR 013 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; First in man

Most Recent Events

21 Oct 2024 According to ExeVir Bio media release, company will present data from this study in a poster presentation on XVR013m, a potent VHH-FC antibody for the prevention and treatment of COVID-19 at ID Week 2024 which will held in Los Angeles from October 16-19, 2024.
11 Jun 2024 New trial record
04 Jun 2024 According to ExeVir Bio media release, company plans clinical trial for COVID-2019 infections (Prevention) in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com